glp-1 obesity drugs news today 2025 Novo Nordisk cuts forecast amid slower sales Global Glucagon-Like Peptide (GLP)-1 Agonists

Mathieu, R

Makani et al., 2011

When paired with Tesamorelin, this clean profile is preserved across the blend, distinguishing it from older secretagogues such as GHRP-6 or hexarelin

It crosses the placenta and should only be used during pregnancy or breastfeeding under the direction of a healthcare provider

The rationale is that localized delivery concentrates the compound at the target tissue, potentially increasing efficacy relative to systemic dose

Pharmacological interventions such as orlistat or GLP-1 receptor agonists may be considered for patients with BMI 30 kg/m who have not achieved adequate weight loss through lifestyle measures alone